{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T02:00:20Z","timestamp":1782698420420,"version":"3.54.5"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.ygyno.2023.01.010","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T11:22:21Z","timestamp":1678274541000},"page":"141-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study"],"prefix":"10.1016","volume":"171","author":[{"given":"Krishnansu S.","family":"Tewari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Sill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Birrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Penson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lois M.","family":"Ramondetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Landrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Oaknin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario M.","family":"Leitao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen E.","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2023.01.010_bb0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"7","key":"10.1016\/j.ygyno.2023.01.010_bb0010","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/jama.2018.10897","article-title":"Screening for cervical cancer: US preventive services task force recommendation statement","volume":"320","author":"US Preventive Services Task Force","year":"2018","journal-title":"JAMA"},{"issue":"RR-05","key":"10.1016\/j.ygyno.2023.01.010_bb0015","first-page":"1","article-title":"Human papillomavirus vaccination: recommendations of the advisory committee on immunization practices (ACIP)","volume":"63","author":"Markowitz","year":"2014","journal-title":"MMWR Recomm. Rep."},{"issue":"1","key":"10.1016\/j.ygyno.2023.01.010_bb0020","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ygyno.2018.10.026","article-title":"Validation of the 2018 FIGO cervical cancer staging system","volume":"152","author":"Matsuo","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.01.010_bb0025","author":"American Cancer Society"},{"key":"10.1016\/j.ygyno.2023.01.010_bb0030","series-title":"Clinical Gynecologic Oncology","article-title":"Invasive Cervical Cancer","author":"Tewari","year":"2017"},{"issue":"27","key":"10.1016\/j.ygyno.2023.01.010_bb0035","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.18.02303","article-title":"Evidence-based treatment paradigms for management of invasive cervical carcinoma","volume":"37","author":"Tewari","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"28","key":"10.1016\/j.ygyno.2023.01.010_bb0040","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2009.21.8909","article-title":"Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervix al carcinoma: a gynecologic oncology group study","volume":"27","author":"Monk","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2023.01.010_bb0045","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ygyno.2011.06.001","article-title":"SCOTCERV: a phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer","volume":"23","author":"Symonds","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2023.01.010_bb0050","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s002800100327","article-title":"Synergistic interaction between topotecan and microtubule-interfering agents","volume":"48","author":"Bahadori","year":"2001","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.ygyno.2023.01.010_bb0055","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ygyno.2003.11.019","article-title":"Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma","volume":"92","author":"Tiersten","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2023.01.010_bb0060","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ygyno.2023.01.010_bb0065","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1470-2045(15)70004-5","article-title":"Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG oncology-gynecologic oncology group protocol 240)","volume":"16","author":"Penson","year":"2015","journal-title":"Lancet Oncol."},{"issue":"10103","key":"10.1016\/j.ygyno.2023.01.010_bb0070","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (gynecologic oncology group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.ygyno.2023.01.010_bb0075","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.1158\/1078-0432.CCR-15-1346","article-title":"Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with\/without bevacizumab: NRG oncology\/GOG study","volume":"21","author":"Tewari","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ygyno.2023.01.010_bb0080","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/bjc.2017.400","article-title":"Impact of tumour histology on survival in advanced cervical carcinoma: an NRG oncology\/Gynaecologic oncology group study","volume":"118","author":"Seamon","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2023.01.010_bb0085","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-20-0276","article-title":"Circulating tumor cells in advanced cervical cancer: NRG oncology \u2013 gynecologic oncology group study 240 (NCT 00803062)","author":"Tewari","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.ygyno.2023.01.010_bb0090","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1996","journal-title":"Cancer Chemother. Rep."},{"key":"10.1016\/j.ygyno.2023.01.010_bb0095","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J. R Stat. Soc. [B]"},{"issue":"13\u201314","key":"10.1016\/j.ygyno.2023.01.010_bb0100","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/sim.4780131321","article-title":"Stopping when the experimental regimen does not appear to help","volume":"13","author":"Wieand","year":"1994","journal-title":"Stat. Med."},{"issue":"3","key":"10.1016\/j.ygyno.2023.01.010_bb0105","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/biomet\/70.3.659","article-title":"Discrete sequential boundaries for clinical trials","volume":"70","author":"Gordan Lan","year":"1983","journal-title":"Biometrika"},{"key":"10.1016\/j.ygyno.2023.01.010_bb0110","series-title":"Analysis of Longitudinal Data. Oxford","author":"Diggle","year":"1993"},{"issue":"19","key":"10.1016\/j.ygyno.2023.01.010_bb0115","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1200\/JCO.2014.58.4391","article-title":"Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505","volume":"33","author":"Kitagawa","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2023.01.010_bb0120","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ygyno.2020.07.026","article-title":"Primary results from CECILIA, a global single-arm phase 2 evaluate bevacizumab, carboplatin and paclitaxel for advanced cervical cancer","volume":"159","author":"Redondo","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"7645","key":"10.1016\/j.ygyno.2023.01.010_bb0125","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nature21386","article-title":"Integrated genomic and molecular characterization of cervical cancer","volume":"543","author":"The Cancer Genome Atlas Research Network","year":"2017","journal-title":"Nature"},{"issue":"7488","key":"10.1016\/j.ygyno.2023.01.010_bb0130","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nature12881","article-title":"Landscape of genomic alterations in cervical carcinomas","volume":"506","author":"Ojesina","year":"2014","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.ygyno.2023.01.010_bb0135","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KeyNote-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2023.01.010_bb0140","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.ygyno.2023.01.010_bb0145","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N. Engl. J. Med."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823000100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823000100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:50:25Z","timestamp":1715820625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825823000100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":29,"alternative-id":["S0090825823000100"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.01.010","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}